TherapeuticsMD, Inc.
TXMD
$2.02
-$0.18-8.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 893.00K | 784.00K | 952.00K | 393.00K | 667.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 893.00K | 784.00K | 952.00K | 393.00K | 667.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 893.00K | 784.00K | 952.00K | 393.00K | 667.00K |
| SG&A Expenses | 1.77M | 984.00K | 1.18M | 1.08M | 879.00K |
| Depreciation & Amortization | 97.00K | 96.00K | 96.00K | 95.00K | 100.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.86M | 1.08M | 1.27M | 1.18M | 979.00K |
| Operating Income | -969.00K | -296.00K | -319.00K | -783.00K | -312.00K |
| Income Before Tax | -580.00K | 50.00K | 545.00K | -668.00K | 83.00K |
| Income Tax Expenses | 32.00K | -- | -- | -32.00K | -31.00K |
| Earnings from Continuing Operations | -612.00K | 50.00K | 545.00K | -636.00K | 114.00K |
| Earnings from Discontinued Operations | -7.00K | 102.00K | 6.00K | -17.00K | 138.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -619.00K | 152.00K | 551.00K | -653.00K | 252.00K |
| EBIT | -969.00K | -296.00K | -319.00K | -783.00K | -312.00K |
| EBITDA | -872.00K | -200.00K | -223.00K | -688.00K | -212.00K |
| EPS Basic | -0.05 | 0.01 | 0.05 | -0.06 | 0.02 |
| Normalized Basic EPS | -0.03 | 0.00 | 0.03 | -0.03 | 0.00 |
| EPS Diluted | -0.06 | 0.01 | 0.05 | -0.06 | 0.02 |
| Normalized Diluted EPS | -0.03 | 0.00 | 0.03 | -0.03 | 0.00 |
| Average Basic Shares Outstanding | 11.58M | 11.57M | 11.57M | 11.55M | 11.53M |
| Average Diluted Shares Outstanding | 11.58M | 11.57M | 11.57M | 11.55M | 11.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |